Taltz

Drug Overview
Product Profiles
Taltz : Axial spondyloarthritis (axSpA)
Taltz : Psoriatic arthritis (PsA)
Taltz : Psoriasis

Figure 1: Taltz for axial spondyloarthritis – SWOT analysis
Figure 2: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 3: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 4: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Taltz for psoriatic arthritis – SWOT analysis
Figure 6: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 7: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 8: Taltz for psoriasis – SWOT analysis
Figure 9: The authors drug assessment summary of Taltz in psoriasis
Figure 10: The authors drug assessment summary of Taltz in psoriasis

Table 1: Taltz drug profile
Table 2: Taltz Phase III trials in axial spondyloarthritis
Table 3: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 4: Taltz drug profile
Table 5: Taltz Phase III data in psoriatic arthritis
Table 6: Taltz ongoing late-phase trials in psoriatic arthritis
Table 7: Taltz drug profile
Table 8: Taltz pivotal trial data in psoriasis
Table 9: Taltz ongoing late-phase clinical trials in psoriasis